{"name":"Vantage Biosciences Ltd","slug":"vantage-biosciences-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxNUm9QRGxtWDBNRm02d21FM2RrYnRWZkhMU2pMckRRV0R0YTNtdkdDdDZ5bXdMYzc5N0V6bUNMSnpDLUxUR3NrbDAxSWRsaTZFTG5tYkVTcG5mWGlHM0JoeXI5RTM4dExZdXNaTEEtUUpZdHVmMjNYWFBNenE3REp0U1JKalRoTmY3V2xIQTF2YmxhWW84SDVsanZtT3kwOWZPYmNmQk04aGlmejhjcGE2aGlBazk5eFRHb2w0U3Zlbm5VRldTZ2lHX2xOYm5mNlE5LTFUdzVscXdodVh4X3VESVNzWQ?oc=5","date":"2025-05-16","type":"pipeline","source":"BioSpectrum Asia","summary":"Targeting inflammation at the source: VX-01 aims to redefine NPDR treatment with first oral therapy - BioSpectrum Asia","headline":"Targeting inflammation at the source: VX-01 aims to redefine NPDR treatment with first oral therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxOejMyazNWUjhlQ2I4djJyRDcxaU1jLUw4TFJLbjdFWU0xdzZqcHE4NVNXMXBDRmc4MkpNTnMxaVZtOFEtNE5KUnllSlpkT3NESno3STUzWG5MZWFmc2xhaWtUX0xFWEhpMEFjWDBGN2RQVkR1MFZnZFk0cHNkc3cwOFhR?oc=5","date":"2025-04-14","type":"trial","source":"Clinical Trials Arena","summary":"First subject dosed in Vantage’s Phase II trial for diabetic retinopathy - Clinical Trials Arena","headline":"First subject dosed in Vantage’s Phase II trial for diabetic retinopathy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxOSnhUMUZwVGZDTGc1MzlSZjFIQWNuRzhvbFhaZnQ4RXNRbkdMdkNFaEJpRmRMUW4tYndjLUhkZHBYVmIzMkNyYkFUT0l4T2FTbThwMDFmOXI2WHR6REszR2dhRU5HSDUwaHNoVGhYZXlDb3c0M09kRjBvMG5oLXJ1MlB1UWRiZ0NrLVRXa2ZuVm00WUpubF96RE9xV1pLeXpPaWNidXFteWJoZzdhYXEtRnIxRlluSmFzN0YxT1JHNEY3YjludGdxVUZXRjgtNUtENkZ6dGloNENISXpTXzlKYlFMSDRiLWlsRWxaSTJzbkNXVkk?oc=5","date":"2025-04-11","type":"trial","source":"Ophthalmology Times","summary":"Vantage Biosciences doses first patient in phase 2 study of VX-01, oral therapy for nonproliferative diabetic retinopathy - Ophthalmology Times","headline":"Vantage Biosciences doses first patient in phase 2 study of VX-01, oral therapy for nonproliferative diabetic retinopath","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxNTThZNENxMVJsd000SExsYTU5a2R3QzdLdWRzOWJOVXJ4Q1V0azdybkh0SHVWMWZueENnQkRub0ljaElhUzVKU2pGdXdKNWJyTTE4YW1YYXl2b1p0YmJsUEhYWjVnYlJ1UXJ6TDVfbGZmQk16S1RSemRnbHlkSHpjRDlmdDYxLU41ZDRIVXF3NHhqcnJ6X1QzZ2FqWVY4c0FzR01GeExkSXR3RHA1dU1aV0hKYzg4ODVLY3RqNmlBWklKOHRjYlhwVWtjcGFwbmxEOUdlelZRVVhrNkhrMU82TGhwZ1NuY1gyUlhab0xtVE1aNXNGaE9kZW02dUg4THlzTzhaa1VYc2kwdXQ4ck9QNVlvVURPQVp2dVRZQzhn?oc=5","date":"2021-05-06","type":"trial","source":"businesswire.com","summary":"Evaluate Acquires Bioscience Advisors, Adding the Most Comprehensive Database of Biopharma Deals to Its Commercial Intelligence Portfolio - businesswire.com","headline":"Evaluate Acquires Bioscience Advisors, Adding the Most Comprehensive Database of Biopharma Deals to Its Commercial Intel","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}